Biomarin Pharmaceutical Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $90.735
- Today's High:
- $92.2847
- Open Price:
- $91.2
- 52W Low:
- $70.73
- 52W High:
- $117.77
- Prev. Close:
- $90.86
- Volume:
- 709783
Company Statistics
- Market Cap.:
- $17.22 billion
- Book Value:
- 24.835
- Revenue TTM:
- $2.17 billion
- Operating Margin TTM:
- 3.5%
- Gross Profit TTM:
- $1.61 billion
- Profit Margin:
- 3.3%
- Return on Assets TTM:
- 0.76%
- Return on Equity TTM:
- 1.58%
Company Profile
Biomarin Pharmaceutical Inc had its IPO on 1999-07-23 under the ticker symbol BMRN.
The company operates in the Healthcare sector and Biotechnology industry. Biomarin Pharmaceutical Inc has a staff strength of 3,082 employees.
Stock update
Shares of Biomarin Pharmaceutical Inc opened at $91.2 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $90.74 - $92.28, and closed at $92.06.
This is a +1.32% increase from the previous day's closing price.
A total volume of 709,783 shares were traded at the close of the day’s session.
In the last one week, shares of Biomarin Pharmaceutical Inc have slipped by -1.04%.
Biomarin Pharmaceutical Inc's Key Ratios
Biomarin Pharmaceutical Inc has a market cap of $17.22 billion, indicating a price to book ratio of 4.4089 and a price to sales ratio of 10.0508.
In the last 12-months Biomarin Pharmaceutical Inc’s revenue was $2.17 billion with a gross profit of $1.61 billion and an EBITDA of $177.14 million. The EBITDA ratio measures Biomarin Pharmaceutical Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Biomarin Pharmaceutical Inc’s operating margin was 3.5% while its return on assets stood at 0.76% with a return of equity of 1.58%.
In Q1, Biomarin Pharmaceutical Inc’s quarterly earnings growth was a negative -58% while revenue growth was a positive 14.8%.
Biomarin Pharmaceutical Inc’s PE and PEG Ratio
- Forward PE
- 31.25
- Trailing PE
- 229.325
- PEG
- 0.6435
Its diluted EPS in the last 12-months stands at $0.4 per share while it has a forward price to earnings multiple of 31.25 and a PEG multiple of 0.6435. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Biomarin Pharmaceutical Inc’s profitability.
Biomarin Pharmaceutical Inc stock is trading at a EV to sales ratio of 9.9386 and a EV to EBITDA ratio of 90.9086. Its price to sales ratio in the trailing 12-months stood at 10.0508.
Biomarin Pharmaceutical Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $6.43 billion
- Total Liabilities
- $598.23 million
- Operating Cash Flow
- $-30012000.00
- Capital Expenditure
- $24.77 million
- Dividend Payout Ratio
- 0%
Biomarin Pharmaceutical Inc ended 2023 with $6.43 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $6.43 billion while shareholder equity stood at $4.66 billion.
Biomarin Pharmaceutical Inc ended 2023 with $0 in deferred long-term liabilities, $598.23 million in other current liabilities, 188000.00 in common stock, $-738347000.00 in retained earnings and $196.20 million in goodwill. Its cash balance stood at $580.07 million and cash and short-term investments were $1.15 billion. The company’s total short-term debt was $9,251,000 while long-term debt stood at $1.08 billion.
Biomarin Pharmaceutical Inc’s total current assets stands at $2.84 billion while long-term investments were $340.64 million and short-term investments were $572.02 million. Its net receivables were $597.91 million compared to accounts payable of $264.78 million and inventory worth $918.92 million.
In 2023, Biomarin Pharmaceutical Inc's operating cash flow was $-30012000.00 while its capital expenditure stood at $24.77 million.
Comparatively, Biomarin Pharmaceutical Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $92.06
- 52-Week High
- $117.77
- 52-Week Low
- $70.73
- Analyst Target Price
- $119.77
Biomarin Pharmaceutical Inc stock is currently trading at $92.06 per share. It touched a 52-week high of $117.77 and a 52-week low of $117.77. Analysts tracking the stock have a 12-month average target price of $119.77.
Its 50-day moving average was $89.13 and 200-day moving average was $97.05 The short ratio stood at 6.33 indicating a short percent outstanding of 0%.
Around 48% of the company’s stock are held by insiders while 10041% are held by institutions.
Frequently Asked Questions About Biomarin Pharmaceutical Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company’s commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A; BMN 331, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial for people living with Hereditary Angioedema (HAE); and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.